Industry
Biotechnology
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Happy Mohamed
March 19, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 10:06 am
Portfolio Pulse from Benzinga Insights
March 18, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Insights
February 09, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 4:52 pm
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 10:16 pm
Portfolio Pulse from Vandana Singh
August 15, 2023 | 7:32 pm
Portfolio Pulse from Lisa Levin
August 15, 2023 | 7:04 pm
Portfolio Pulse from Lisa Levin
August 15, 2023 | 6:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.